kabutan

Chordia Therapeutics Inc.(190A) Summary

190A
TSE Growth
Chordia Therapeutics Inc.
128
JPY
+6
(+4.92%)
Jan 29, 3:08 pm JST
0.83
USD
Jan 29, 1:08 am EST
Result
PTS
outside of trading hours
126.9
Jan 29, 3:07 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.99
Yield
ー%
Margin Trading Ratio
531.43
Stock Price
Jan 29, 2026
Opening Jan 29, 9:00 am
124 JPY 0.80 USD
Previous Close Jan 28
122 JPY 0.79 USD
High Jan 29, 12:32 pm
129 JPY 0.84 USD
Low Jan 29, 9:01 am
121 JPY 0.78 USD
Volume
1,022,500
Trading Value
0.13B JPY 0.84M USD
VWAP
126.27 JPY 0.83 USD
Minimum Trading Value
12,800 JPY 83 USD
Market Cap
9.11B JPY 0.06B USD
Number of Trades
309
Liquidity & Number of Trades
As of Jan 29, 2026
Liquidity
Slightly High
1-Year Average
473
1-Year High Apr 25, 2025
4,017
Margin Trading
Date Short Interest Long Margin Positions Ratio
Jan 23, 2026 0 4,467,300
Jan 16, 2026 0 4,396,800
Jan 9, 2026 0 3,971,100
Dec 26, 2025 0 4,052,800
Dec 19, 2025 0 4,385,500
Company Profile
Chordia Therapeutics Inc. engages in the development of cancer therapeutics targeting RNA regulation stress.
Sector
Pharmaceuticals
Chordia Therapeutics Inc. is a drug discovery venture company specializing in the research and development of novel anti-cancer drugs targeting RNA regulation stress. The company has multiple pipelines including CLK inhibitors, MALT1 inhibitors, and CDK12 inhibitors, aiming to create groundbreaking first-in-class pharmaceuticals. Clinical trials are currently underway for acute myeloid leukemia, ovarian cancer, and other indications. Chordia Therapeutics actively promotes collaborative research and licensing partnerships with universities, public institutions, and pharmaceutical companies to achieve efficient drug discovery operations. The company is also expanding its partnering strategy, as exemplified by the licensing agreement for MALT1 inhibitors with Ono Pharmaceutical Co., Ltd.